Status Active legal-status Critical Current Anticipated expiration legal-status Critical Links Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Family has litigation Priority claimed from EP12172739 external-priority Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS Priority to US15/958,236 priority Critical patent/US11033499B2/en Publication of US20180235888A1 publication Critical patent/US20180235888A1/en Priority to US17/320,436 priority patent/US20210275458A1/en Application granted granted Critical Publication of US11033499B2 publication Critical patent/US11033499B2/en First worldwide family litigation filed litigation Critical (B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. Original Assignee Novo Nordisk AS Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Pedersen Erik Skibsted Current Assignee (The listed assignees may be inaccurate. ( en Inventor Simon Bjerregaard Jensen Per Sauerberg Flemming S. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number US15/958,236 Other versions US20180235888A1 Google Patents Tablet formulation comprising a GLP-1 peptide and a delivery agentĭownload PDF Info Publication number US11033499B2 US11033499B2 US15/958,236 US201815958236A US11033499B2 US 11033499 B2 US11033499 B2 US 11033499B2 US 201815958236 A US201815958236 A US 201815958236A US 11033499 B2 US11033499 B2 US 11033499B2 Authority US United States Prior art keywords tablet ethoxy glp peptide nac Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US11033499B2 - Tablet formulation comprising a GLP-1 peptide and a delivery agent US11033499B2 - Tablet formulation comprising a GLP-1 peptide and a delivery agent
0 Comments
Leave a Reply. |